A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
{{output}}
Preclinical studies have shown that the combined inhibition of EGFR and NF-kB pathways to target the RalB/TBK1 pathway led to synergistic antitumor activity. Based on this rationale, we conducted a Phase I dose-escalation study combining the EGFR inhibitor erl... ...
